🇺🇸 FDA
Patent

US 10611998

Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

granted A61KA61K35/12A61P

Quick answer

US patent 10611998 (Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury) held by The Regents of the University of California expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K35/12, A61P, A61P25/00, A61P25/28